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ABSTRACT 
BACKGROUND: COPD represents a multifactorial lung disorder with high morbidity and 
mortality. Despite intensive research concerning the underlying disease mechanisms, the 
involvement of the CD200/CD200R axis in supporting or preventing the onset of COPD has not 
yet been addressed. Since the CD200/CD200R axis is crucially implicated in the maintenance 
of pulmonary immune homeostasis, we hypothesized that it might be involved in controlling the 
onset of COPD.  
METHODS:  To address this, we analyzed serum samples from COPD patients and normal 
controls for soluble (s) CD200 and correlated the data to COPD-relevant clinical parameters. In 
addition, basic studies were conducted in CD200-deficient and wild-type mice in which COPD-
like inflammation was induced with elastase/LPS followed by lung and serum component 
analysis.  
RESULTS: We observed a positive correlation between serum sCD200 and IL-6 levels as well 
as a trend towards a negative correlation of sCD200 with Vitamin D3 in COPD patients. Further 
investigations in mice revealed that despite elevated serum concentration of MMP-9 in 
CD200KO mice the early onset of COPD-like lung inflammation was similar in CD200-deficient 
and wild-type animals in terms of immune cell infiltration, emphysematous changes and mucus 
overproduction.  
CONCLUSIONS: While our murine studies suggest that the co-inhibitory molecule CD200 does 
not appear to play a prominent role in the early onset of COPD-like features, correlation of 
sCD200 serum levels with COPD-related parameters in humans with established disease 
revealed that the CD200/CD200R axis may be mechanistically linked to the disease course in 
COPD patients. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a complex lung ailment that is characterized 
by chronic airflow obstruction [1], small airway and vascular remodeling [2] and mucus over-
production [3]. The World Health Organization estimates COPD to be the 3rd leading cause of 
death by 2030 [4]. Pulmonary emphysema and chronic inflammation represents the clinical 
hallmarks of COPD, marked by alveolar space enlargement [5] and lung parenchymatic 
destruction [6]. This persistent pulmonary inflammation comprises mainly of neutrophils, 
macrophages [8] and lymphocytes [10]. These cellular components secrete an array of 
inflammatory cytokines and matrix-metalloproteinases (MMPs) to potentiate emphysema 
formation and systemic spillage is usually evident during disease progression [7]. Together, 
pulmonary tissue damage mediated by mucosal immune cells following an initial inflammatory 
trigger plays a principal role in the disease progression in COPD patients [8]. Thus, improved 
understanding concerning immunological mechanisms are needed for the development of 
targeted immune-intervention.   
The CD200/CD200 receptor (CD200R) axis has been reported to control myeloid cell activation 
[9, 10] and to be crucially involved in the maintenance of lung immune homeostasis [11] in both 
human and mice [12, 13]. The CD200 molecule is expressed on airways epithelial cells, 
endothelial cells and T cells [9, 14], whereas the CD200R molecule is predominantly expressed 
on airway macrophages and neutrophils [13].  
In human studies, a new COPD therapeutic, adenosine A2B agonist, enhances CD200 
expression in human airway epithelial cells, indicating the anti-inflammatory quality of the drug 
[15].  There exist soluble (s) forms of CD200 and its receptor CD200R in human sera [16] that 
are produced either by membrane shedding [17] or by mRNA splicing [18]. Several clinical 
investigations have demonstrated elevated serum levels of sCD200 in patients with type 2 
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diabetic foot and nephropathy [19], bullous pemphigoid [20], psoriasis vulgaris [21], SLE [16] 
and Samter´s syndrome [22]. The fact that the level of sCD200 in serum is elevated in several 
diseases might indicate both a possible implication of the CD200/CD200R axis in inflammatory 
diseases and also imply a potential use of sCD200 as a biomarker. In animal studies, CD200-/- 
mice were shown to develop excessive lung inflammation with enhanced neutrophils [23] and T 
lymphocytes [24] infiltration into the lung, and thereby succumb to severe tissue damage 
following pulmonary infection [13].  
In this study, we analyzed serum concentrations of sCD200 in COPD patients and normal 
controls and correlated the data with COPD-relevant clinical parameters. Next to analyses in 
patients with advanced-stage COPD, we experimentally addressed whether the 
CD200/CD200R regulatory axis might be functionally involved in immune cell control in the lung 
during the developmental phase of COPD.  
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MATERIALS & METHODS 
Human subjects  
50 serum samples were collected from COPD patients (36 men, 14 women) and 29 serum 
samples were collected from age- and gender matched normal controls (19 men, 10 women) at 
the Pneumology Unit, Magdeburg University Hospital, Magdeburg, Germany and the Helmholtz 
Centre for Infection Research (HZI), Braunschweig, Germany. The average age of the patients 
and normal controls were 66.7 and 61.6 years, respectively. All subjects were given the written 
informed consent and the study protocol was performed in accordance with the declaration of 
Helsinki and approved by the local ethic committee of the University of Magdeburg, Germany 
(Aktenzeichen 12/11). The characteristics of COPD patients and normal donors are given 
(Table 1).  
Mice 
7-10 weeks old female CD200KO C57BL/6 mice (Ophthalmology Research Unit, University of 
Bristol, United Kingdom) and age- and sex-matched C57BL/6 wild-type mice (Harlan 
Winkelmann, Rossdorf, Germany) were used. CD200KO (n=14) and wild-type mice (n=28) were 
maintained under specific pathogen–free conditions in the animal facility at HZI, Braunschweig, 
Germany. Animal experiments were conducted according to the institutional guidelines and the 
study was ethically approved by the Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit (33.19-42502-04-15/1750).   
Elastase/LPS exposure 
COPD-like features were induced in both CD200KO and C57BL/6 wild-type mice by repeated 
intranasal exposure to elastase and lipopolysaccharide (LPS) as described previously [25], for 
two and four consecutive weeks (Fig. 1A). As negative control, mice were exposed to 50% 
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glycerol (carrier, elastase preparation) and phosphate-buffered saline (PBS) (LPS solvent). Mice 
were sacrificed one week after the final exposure to LPS or PBS for further investigations.  
Lung Volumetry and Histology 
Excised lungs were immersion fixed in 4 % formaldehyde for up to 48 hrs. The volume of each 
lung was estimated by Scherle´s displacement method [26] and the lung volume was 
normalized to the respective total body weight of the mice. For histology, paraffin-embedded 
tissues were cut at 3 μm and tissue sections were mounted on SuperfrostPlus adhesive glass 
slides (Menzel-Gläser; Braunschweig, Germany). Tissue sections were stained with 
hematoxylin and eosin (H&E) for histological examination. Periodic acid-Schiff (PAS) reaction 
was performed to stain mucins. To evaluate histopathological lesion, the inflammatory pattern 
(peribronchial, perivascular) and the immune cell compositions were determined and the 
occurrence of neutrophils, alveolar macrophages and lymphocytes was scored (none=0, 
minimal=1, mild=2, moderate=3, severe=4). A semi-quantitative evaluation of the mucus 
production was performed, the cellular staining intensity (weak=1/strong=2) and the positive 
cells within bronchi (none=0, scattered=1, multifocal=2, diffuse=3) were assessed. Finally, 
emphysematous changes were determined (none=0, minimal=1, mild=2, moderate=3, 
severe=4).  
ELISA 
Serum levels of total MMP-9 (1:50 dilutions) (Cat. # MMPT90) (R&D systems) in elastase/LPS 
exposed mice were determined according to the manufacturer’s instructions. Serum levels of 
sCD200 (Cat. # SEK 10886) (Sino Biologicals Inc.) and TNFα (Cat. # DTA00C) (R&D systems) 
in COPD patients and normal controls were quantified according to the manufacturer´s 
instructions. All analyses were done in duplicate. 
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Immunoturbidimetry 
Serum levels of high-sensitivity C-reactive protein (hsCRP) in COPD patients were quantified by 
turbidimetry (800 nm/570 nm) using a cobas c 311 analyzer (Roche).  
Assay for cytokine and vitamin profiles 
Quantification of vitamin D ((Vitamin-D-1, 25-OH) and IL-6 cytokine in the serum samples of 
COPD patients was performed as routine procedure at the pneumology unit, University Hospital 
Magdeburg.   
 
Statistical analysis 
Non-parametric Mann-Whitney test was used to compare elastase/LPS exposed mice to 
glycerol/PBS exposed control animals, elastase/LPS exposed CD200KO to C57BL/6 wild-type 
controls, serum MMP-9 levels in the mouse model and the serum sCD200 levels in COPD 
patients compared to normal controls. Two-tailed p-value<0.05 were considered significant.  
 RESULTS  
 
Serum sCD200 concentration is positively correlated to the abundance of the pro-
inflammatory cytokine IL-6 in human COPD patients 
Since increased serum levels of sCD200 in patients with inflammatory diseases have been 
shown [20, 21], we sought to analyze sera of COPD patients and normal controls for the 
presence of sCD200. While sCD200 was well detectable in sera of normal and diseased 
donors, we did not observe any significant differences (Fig 1). However, further correlation of 
COPD-relevant clinical parameters with serum sCD200 levels revealed a significant positive 
correlation between sCD200 and IL-6 (Table 2). A positive correlation was also observed with 
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the age of the patient, but not in normal controls (Table 2). Although not significant, there was a 
trend towards a negative correlation with vitamin-D-1,25-OH in COPD patients. No correlation 
was found between sCD200 and TNFα, CRP and GOLD stage of the patients.  
Induction of a COPD-like phenotype in mice by repetitive elastase/LPS exposure  
Since serum sCD200 were correlated with COPD-related parameters in patients with 
established COPD, we next aimed to study the role of the CD200/CD200R axis in early stages 
of COPD development. Here, we utilized a previously described elastase/LPS mouse model 
[25] that resulted in hallmark features of COPD such as immune cell infiltration, emphysematous 
changes and mucus overproduction. Accordingly, 4 weeks of elastase/LPS exposure (Fig 2A) 
induced marked inflammation in C57BL/6 mice with significant neutrophils (Fig 2B) and 
lymphocytes influx (Fig 2C), overall airway inflammation, increased alveolar macrophages influx 
and emphysematous changes (Fig 2D and E), although the latter two parameters did not reach 
statistical significance. However, we observed significantly increased mucin production (Fig 2D 
and 2E). Thus, elastase/LPS exposure resulted in the induction of COPD-like features in wild-
type mice and could be used to study the role of the CD200/CD200R axis in COPD-like lung 
inflammation. 
CD200-deficiency does not affect the onset of COPD-like features in mice following 
elastase/LPS exposure  
Since the CD200/CD200R axis was reported to be involved in lung immune homeostasis, we 
expected an early and augmented inflammatory immune cell infiltration during the 
developmental stage of COPD-like inflammation in the absence of CD200. To experimentally 
address this hypothesis, we analyzed for COPD-related inflammatory alterations in the lung at 2 
weeks and 4 weeks post initial elastase/LPS treatment. Unexpectedly, we observed a slight (but 
not significant) reduction in neutrophil (Fig 3A), lymphocytes (Fig 3B) and alveolar macrophage 
10 
 
(Fig 3E) recruitment and an overall slightly reduced inflammation score (Fig 3E) in CD200KO 
mice compared to control mice (Fig 3D) (for week 4). No differences were observed regarding 
emphysematous changes (Fig 3E), lung volume (Fig 3C) and mucus production (Fig 3E) 
between CD200-deficient and wild-type animals. Thus, the CD200/CD200R axis does not seem 
to play a dominant role in the early development of a COPD-like phenotype in mice.  
Increased serum MMP-9 levels were detected in CD200-deficient mice following 
elastase/LPS exposure 
 Although we did not observe obvious morphological differences in CD200KO and wild-type 
animals following elastase/LPS exposure, we sought to determine the pro-inflammatory 
cytokine/chemokine (IL-1β, IL-6, TNF-α, IL-10 as well as the chemoattractant MCP-1) response 
in the bronchoalveolar lavage fluid (BALF). However, only nominal concentrations of these 
cytokines were detectable and no differences between the CD200KO and wild-type mice were 
observed (data not shown). Since MMPs are crucially involved in the development of 
emphysematous lesion in COPD, we also analyzed the levels of MMP-9, one of the lead MMPs 
in emphysema formation [27]. Indeed, we observed significantly increased concentrations of 
MMP-9 in 4 weeks elastase/LPS exposed CD200KO mice compared to wild-type control 
animals (Fig 4). Thus, serum MMP-9 concentration in CD200KO mice is elevated compared to 
wild- type mice in animals with established COPD-like features. 
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DISCUSSION 
To our knowledge, this is the first study to address the role of the immune-inhibitory CD200 
molecule in COPD patients as well as in COPD-like lung inflammation in mice. Our rational to 
conduct the study was based on the well-known critical role of the CD200/CD200R axis in 
controlling lung inflammation and maintenance of lung homeostasis [13] predominantly by 
inhibition of airway macrophage activation [11]. Since therapeutic intervention aiming at targeted 
inhibition of neutrophil and macrophage activation is given a priority in COPD treatment 
regimen, we sought to determine whether CD200 would be mechanistically linked to loss of 
pulmonary immune homeostasis and thereby may represent a novel candidate molecule for 
improved treatments.   
To unravel the potential role of CD200 in human COPD, we first addressed whether serum 
levels of sCD200 would be altered in COPD patients compared to normal controls. Although 
sCD200 was shown to influence regulatory T cells (Tregs) expansion [28], the exact function of 
serum sCD200 in human diseases remains obscure. For instance, elevated serum sCD200 
levels were correlated with disease severity in patients with inflammatory skin diseases [29], 
whereas it correlated with myeloid-derived suppressive cells in glioblastoma patients [30], 
pointing to both pro- and anti-inflammatory effects. Nevertheless, we could not detect any 
significant alterations in sCD200 levels in COPD patients. However, we may speculate that 
multifactorial stimuli like smoking or recurrent infections may result in decreased CD200 cell-
surface expression, which may limit the membrane shedding and account for reduced sCD200 
in COPD patients. Alternatively, the role of CD200 might be negligible in COPD. Intriguingly, a 
positive correlation of sCD200 with the pro-inflammatory cytokine IL-6 and age and a trend for 
inverse relation with vitamin D3 provided a first hint for a potential pro-inflammatory role of 
sCD200 in COPD pathogenesis. Vitamin D3 consumption was already shown to induce CD200 
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expression in airway immune cells, which was impaired in patients with chronic lung disease, 
suggesting the role of vitamin D to restrain airway inflammation [20]. One possible explanation 
could be that circulating sCD200 might block the cell-surface interactions between CD200 and 
CD200R to mediate their immune-inhibitory functions. Functional studies are required to prove 
this notion. Also, this study lacks the required power of analysis, which could be substantiated 
with a larger COPD cohort.  
To further explore the role of the CD200/CD200R axis in COPD, we utilized the elastase/LPS 
exposure model to induce COPD-like lung inflammation in mice [25]. The obvious advantage of 
this model is that the COPD-like phenotype develops relatively fast and essentially mimics all 
hallmark features of human COPD. Accordingly, elastase/LPS treatment led to inflammation, 
especially mediated by neutrophils, macrophages and lymphocytes, development of 
emphysematous lesions and robust mucus over-production.  
Since studies with CD200-deficient mice revealed a massive accumulation and activation of 
myeloid cells in various disease models [9, 31], we also expected CD200KO mice to exhibit 
increased myeloid cell influx following elastase/LPS exposure and a more severe COPD 
progression. Contradictorily, no significant differences in COPD-relevant histopathological 
parameters were observed. One possible reason could be the existence of other lung regulatory 
mechanisms that might compensate for the functional loss of the CD200 molecule and may 
control the myeloid cell activation. Indeed, such compensatory mechanisms underlining the 
phenomenon of biological robustness of immune-regulatory circuits have been reported [32-34].  
Another possible explanation could be that in addition to CD200 other, yet unknown, inhibitory 
ligands for CD200R may exist. This is not irrelevant since only few years ago, a high-throughput 
screening of a receptor array identified ICOS-L as a ligand for CD28 on human T cells in 
addition to the well-established receptor molecule ICOS [35].  
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Concerning our observation that, in general, disease progression monitored in our mouse model 
might not entirely reflect the disease course in human COPD, we may speculate that this could 
be related to the fact that our laboratory mice are kept under specific pathogen-free conditions, 
i.e. in contrast to humans they exhibit a very limited microbial flora and are less exposed to 
internal antigenic triggers and infectious agents, which might act as external triggers, to 
stimulate disease progression, as seen in COPD patients.    
Despite negligible histological effects, we detected increased serum levels of MMP-9 in CD200-
deficient animals. The main sources of MMP-9 are usually neutrophils, alveolar macrophages 
[36] and lung epithelial cells [37]. A possible reason for increased serum MMP-9 levels could be 
that the absence of the CD200 results in enhanced susceptibility of lung epithelial cells to the 
action of elastase and LPS. In support of this, it has been shown that the lack of PD-L1, another 
co-inhibitory ligand binding to the PD-1 molecule on T cells, resulted in impaired inhibition of 
MMP-9 secretion in neutrophils [38]. Importantly, we have analyzed total secreted MMP-9 that 
includes both inactive and active forms of serum MMP-9. Here, the increased serum MMP-9 
may account for the inactive form, which might not necessarily result in enhanced 
emphysematous changes.   
In this study, we exclusively focused on the question whether CD200-deficiency would alter the 
development of COPD-like inflammation in mice. Another approach would be either to induce 
overexpression of CD200 or alternatively to modulate CD200R by fusion protein or antibodies to 
study the implication of CD200/CD200R axis on the disease course. The rationale behind 
targeted modulation of the CD200R is that the receptor has been shown to be upregulated on 
pulmonary myeloid cells even under strong LPS stimulus [13]. Furthermore, unlike other 
receptor-ligand pairs [39, 40], CD200-bearing cells do not mediate downstream signals due to 
its short cytoplasmic tail that has no signaling motifs. Hence the central response following 
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CD200/CD200R interaction is mediated through CD200R-bearing myeloid cells [9]. Therefore, 
we suggest that future investigations should consider fine tuning of CD200R expression on 
myeloid cells for achieving direct signaling impact in macrophages and neutrophils on disease 
outcomes. Together, our data obtained in the murine elastase/LPS COPD model implied that 
the CD200/CD200R axis does, if at all, only play a minor role in COPD development.  
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CONCLUSIONS 
This study demonstrated a positive correlation between serum sCD200 and IL-6 and age of 
COPD patients. Despite strong evidences for the implication of the CD200/CD200R axis in 
preservation of lung homoeostasis, no obvious impact of CD200-deficiency on the development 
of murine COPD-like lung inflammation was observed. Nevertheless, we do not exclude that 
investigations performed in cigarette smoke-induced COPD models or utilizing antibody-
mediated blockade of the CD200R could still uncover a potential mechanistic link of the 
CD200/CD200R axis to the multifactorial disease course in COPD patients. 
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COPD- Chronic Obstructive Pulmonary Diseases; CRP- C-Reactive Protein; GOLD- Global 
Initiative for Chronic Obstructive Lung disease; H&E- hematoxylin and eosin; IL- Interleukin; KO- 
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FIGURE LEGENDS 
 
Figure 1. Comparable sCD200 serum levels in COPD patients and normal controls. 
Graphs represent circulating serum levels of sCD200 from COPD patients (n=50) and normal 
controls (n=29). The dots represent data obtained for individual patients and control subjects. P-
values were calculated using the non-parametric Mann-Whitney test.  
Figure 2. Induction of a COPD-like phenotype in C57BL/6 wild type mice by repeated 
elastase and LPS exposure (A) Schematic representation of the COPD model based on 
repetitive intranasal administration of elastase/ LPS for 4 weeks. (B) Histological neutrophil and 
(C) lymphocyte scoring in the lung tissues of elastase/LPS exposed mice (n=10) and control 
treated mice (n=8). (D) Representative histopathology of COPD-like phenotype (a-h) in wild type 
mice, 5 weeks after initial treatment: (a-d) elastase and LPS treated mice, (a) inflammation 
including neutrophils and lymphocytes: score: 3 (moderate), H&E staining, scale bar: 50μm, 
inlay bar: 20μm; (b) alveolar macrophages infiltration: score 2,5 (mild to moderate), H&E 
staining, scale bar: 50μm; (c) emphysema: score 3 (moderate), H&E staining, scale bar: 100μm; 
(d) mucin staining in large bronchi: score 2 (strong cellular signal) and 2,5 (multifocal to diffuse), 
PAS-reaction, scale bar: 100μm, inlay bar: 20μm. (e-h) Glycerol and PBS treated mice, (e) 
inflammation: score 0 (none), H&E staining, scale bar: 50μm; (f) alveolar macrophages 
infiltration: score 0 (none), H&E staining, scale bar: 50μm; (g) emphysema: score 1 (minimal), 
H&E staining, scale bar: 100μm; (h) mucin staining in large bronchi: score 1 (weak) and 2 
(multifocal), PAS-reaction, scale bar: 100μm. (E) Represents histological inflammation 
(neutrophils, lymphocytes, alveolar macrophages), alveolar macrophages, emphysema and 
mucus production scoring in the lung tissues between COPD induced (n=10) and control mice 
(n=8). The dots represent the data obtained for individual mice. Data obtained were pooled from 
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two independent experiments. P-values were calculated using non-parametric Mann-Whitney 
test.  
Figure 3. CD200-deficiency does not affect the onset of COPD-like lung inflammation in 
elastase/LPS-exposed mice. (A) Histological neutrophil and (B) lymphocyte scoring in the lung 
tissues of elastase/LPS exposed CD200KO (n=7) and wild-type mice (n=5) following 2 and 4 
weeks of treatment. (C) Lung volume (in %, Scherle method) in elastase/LPS exposed 
CD200KO mice (n=7) and wild-type (n=5) following 2 and 4 weeks of treatment. (D) 
Representative histopathology of COPD-like phenotype (a-h), 5 weeks after initial treatment with 
elastase and LPS in (a-d) wild type mice and in (e-h) CD200KO mice: (a) inflammation including 
neutrophils and lymphocytes: score 3 (moderate), H&E staining, scale bar: 50μm, inlay bar: 
20μm; (b) alveolar macrophages infiltration: score 2,5 (mild to moderate), H&E staining, scale 
bar: 50μm; (c) emphysema: score 3 (moderate), H&E staining, scale bar: 100μm; (d) mucin 
staining in large bronchi: score 2 (strong) and 2,5 (multifocal to diffuse), PAS-reaction, scale 
bar: 100μm, inlay bar: 20μm. (e) inflammation: score 2 (mild), H&E staining, scale bar: 50μm, 
inlay bar: 20μm, (b) alveolar macrophages infiltration: score 2,5 (mild to moderate), H&E 
staining, scale bar: 50μm; (c) emphysema: score 3 (moderate), H&E staining, scale bar: 50μm, 
inlay bar: 20μm; (d) mucin staining: score 2 (strong) and 2 (multifocal), PAS-reaction, scale bar: 
100μm, inlay bar: 20μm. The bar graphs represents (E) inflammation (neutrophils, lymphocytes, 
alveolar macrophages), alveolar macrophages, emphysema and mucus production scoring in 
the lung tissues between CD200KO COPD induced mice (n=7) and wild-type COPD induced 
(n=5) on week 2 and 4.  The bar graphs are represented as a mean with SEM. P-values were 
calculated using non-parametric Mann-Whitney test.  
 Figure 4. CD200-deficiency is associated with increased serum levels of MMP-9 in mice 
following 4 weeks of elastase/LPS exposure. Graphs represent serum levels of total MMP-9 
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of elastase/LPS exposed CD200KO (n=7) and wild-type mice (n=5) after 2 (white bars) and 4 
(black bars) weeks treatment. Bar graphs are represented as mean with SEM. P-values were 
calculated using the non-parametric Mann-Whitney test.  
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Parameters             COPD patients          Normal controls 
Basic Paramaters 
   Number of subjects (n) 
    Age (Mean years) 
    Gender (Men/Women) 
    BMI (Kgm2)  
Clinical Paramaters 
     GOLD (I/II/III/IV/nd) 
     IL-6 (pg/ml) 
     TNF-α (pg/ml) 
     CRP (ng/ml) 
     Vitamin-D-1,25-OH (ng/ml) 
Pulmonary function tests 
     VC% 
     FEV1 (%) 
     DLCO (%) 
 
50 
66.7 
36/14 
27 (14-42) (n=39) 
 
(3/18/8/9/12) 
6 (0-41) (n=38) 
2 (0-21) (n=37) 
8 (1-75) (n=34) 
50 (22-84) (n=39) 
 
77 (44-134) (n=38) 
54 (23-113) (n=39) 
          53 (23-92) (n=35) 
 
 
29 
61.6 
19/10 
- 
 
 
 
- 
- 
- 
- 
- 
 
 
 
        - 
- 
- 
 
Table 1: Characteristics of COPD patients and normal controls. n = number of patients and 
controls. BMI - body mass index; GOLD – global initiative for chronic obstructive lung disease; 
GOLD I - mild; GOLD II - moderate; GOLD III - Severe; GOLD IV – very severe; nd - not 
defined. IL - interleukin; TNFα – tumor necrosis factor (alpha); CPR - C-reactive proteins; 
Pulmonary function tests (values show % of predicted); VC – vital capacity; FEV1 – forced 
expiratory volume in one second; DLCO-diffusing capacity of the lung for carbon monoxide. 
Data are shown as median (min-max) in number of patients.  
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Parameters sCD200  
Age (P/r) 
GOLD stage (P/r) 
CRP (P/r) 
Vitamin-D-1,25-OH (P/r) 
IL-6 (P/r) 
TNF-α (P/r) 
0.04*/0.27 
0.49/0.11 
0.20/0.22 
0.07‡/-0.28 
0.01*/0.38 
0.83/-0.03 
GOLD - Global Initiative for Chronic Obstructive Lung Diseases;  
CRP - C-reactive protein; IL - Interleukin; TNF-α - Tumor Necrosis Factor- alpha. 
*indicates significant P-values; ‡ indicates tendencies. 
 
Table 2. P-values and r-values from Spearman´s correlation rank test between sCD200 and clinical 
parameters in COPD patients. 
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